Month: August 2019

Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG.

The health insurance company Anthem is making preparations to once again offer plans on the state exchange, a reversal of its decision to exit it two years ago over volatility in the individual health insurance marketplace.

Medicare-for-All proposals have sparked discussion about the role of private health insurance in the U.S. health care system. Some of the current Medicare-for-All proposals would essentially eliminate private insurance.

Though support or opposition for “Medicare for All” is dominating the 2020 primary headlines, a large group of Americans is more ambivalent about the proposal, a new survey shows. 

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG.

California’s attorney general touted a legal victory last week against drugmakers who he said made secretive, backroom deals to keep less expensive drugs off the market.

San Jose has joined cities across the country in calling out the makers and sellers of prescription painkillers like OxyContin and Percocet for furthering the nation’s opioid epidemic.

The Centers for Medicare & Medicaid Services (CMS) is planning to launch updates to its Medicare Plan Finder (MPF) this month after a report from a government watchdog flagged significant usability concerns with the tool. 

Drug companies, hospitals and dialysis companies spent millions of dollars in the first half of the year fighting bills that would have hurt their bottom lines, according to lobbying reports filed last week.

A year after calling proposals allowing Americans to import cheaper drugs from Canada a “gimmick,” Health and Human Services Secretary Alex Azar said the federal government is “open for business” on such a strategy.